波士顿科学Boston Scientific Corporation (BSX) 2016年年度报告「NYSE」.pdf

1、BOSTON SCIENTIFIC2016 ANNUAL REPORTTransforming Lives.FINANCIAL HIGHLIGHTSThroughout this Annual Report,unless otherwise noted,all revenue and other growth rates represent 2016 growth compared to 2015.Information on or connected to our website(or the website of any third party)referenced in this Ann

2、ual Report is in addition to and not a part of or incorporated by reference into this Annual Report.1 Operational sales/revenues and growth rates are non-GAAP measures that exclude the impact of changes in foreign currency exchange rates;see reconciliation of GAAP sales/revenues and growth rates on

3、pages 11 and 12.2 Organic growth rates are non-GAAP measures that exclude the impact of changes in foreign currency exchange rates and the salesfrom the acquisitions of the interventional business of Bayer AG,the American Medical Systems male urology portfolio and EndoChoice Holdings,Inc.over the pr

4、ior year period;see reconciliation of GAAP sales/revenues and growth rates on pages 11 and 12.3 Adjusted operating margin,adjusted earnings per share and their related growth rates are non-GAAP measures that exclude the impact of goodwill and intangible asset impairment charges,acquisition-and dives

5、titure-related net charges and credits,restructuring and restructuring-related net charges,litigation-related net charges,pension termination charges,debt extinguishment charges,discrete tax items and amortization expense.2016 Operational Sales by Product Category1(Dollars in millions)2016GrowthCard

6、iovascular Interventional Cardiology$2,524 13%Peripheral Interventions1,09312%Rhythm Management Cardiac Rhythm Management1,9943%Electrophysiology 261 5%MedSurg Endoscopy 1,565 10%Urology and Pelvic Health1,06545%Neuromodulation 574 12%$9,076 12%2016 Operational Sales by Region1(Dollars in millions)2